Brief: Ascentage Pharma Group Says APG-2575 Receives Approvals For Two Phase Ib/II Clinical Studies In China
23/11/2020 13:06
Nov 23 (Reuters) - Ascentage Pharma Group International
6855.HK :
* APG-2575 RECEIVES APPROVALS FOR TWO PHASE IB/II CLINICAL
STUDIES
IN CHINA FROM NMPA
Source text for Eikon: urn:newsml:reuters.com:*:nPnbGRjgYav
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up